The global infectious disease therapeutics market size was valued at USD 115 billion in 2022 and is expected to reach around USD 164.58 billion by 2032, poised to grow at a compound annual growth rate (CAGR) of 3.7% during the forecast period 2023 to 2032.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
Infectious diseases spread from one person to another by indirect or direct contact. For treating infectious diseases medicines which are anti-infective in nature need to be consumed by the patients. These diseases are mainly caused due to pathogens like viruses, bacteria, fungi and parasites. The defense system of the host is acted upon directly with a view to target the organism that is causing the disease and cure is brought into effect. The huge number of people belonging to the geriatric population has emerged as a great opportunity for the growth of the infectious disease therapeutics market.
The outbreak of the and make was an example of an infectious disease which was caused due to coronavirus. The occurrence of this pandemic emerged as a major growth factor for the infectious disease therapeutics market. The huge number of technologically advanced medicines that were launched during the course of the pandemic has helped the market to record a tremendous revenue over the period of time.
The increasing prevalence of infectious diseases in the society has emerged as a major growth factor for the therapeutic system as well. Advanced medicines have been launched by the key market players for treating infectious diseases with a view to produce better profits. Initiatives have been taken by the government for providing advanced facilities to the citizens in order to treat infectious diseases.
A huge number of people who belong to the genetic population has emerged as a major opportunity for the growth of the market. A rise in the disposable income available with the people has emerged as a major opportunity as well. A high disposable income enables the people to opt for advanced treatment options which helps the growth of the market.
Insurance companies are providing attractive reimbursement policies that are supporting the expenses of the people and hence they are opting for better treatment options to get themselves treated in a shorter period of time. The extensive research and development programs carried out by the key market players with a view to introduce modern medicines into the society has help the market to record a considerable revenue over the period of time.
| Report Coverage | Details |
| Market Size in 2023 |
USD 118.68 Billion |
| Market Size by 2032 |
USD 164.58 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 3.7% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Mode of Treatment, Target Organism, Infection Type, Distribution Channel and Geography |
| Companies Mentioned |
Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K), Merck & Co. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), AstraZeneca (U.K), Mylan N.V. (U.S.), Novartis AG (Switzerland), Sanofi (France) |
Key Market Drivers
Key Market Challenges
Key Market Opportunities
On the basis of mode of treatment, the segment of drug has emerged as the fastest growing market owing to its largest share in the global economy. Increasing demand for advanced drugs in the market has helped in this segment to record a considerable revenue over the period of time and it's foreseen to continue its growth in a similar fashion during the future as well. The huge number of people belonging to the geriatric population has emerged as a major opportunity for the segment of drugs as it is the most common line of treatment opted by these people. The availability of medicines over the counter has also proved to be a major opportunity for the growth of the drug segment. Increasing disposable income available with the people has enabled them to opt for advanced drugs available in the market for the purpose of treatment. The other segment which has been discussed under this category includes vaccines which has become a common entity after the birth of a child to the period up till when new diseases keep on emerging into the market along with their vaccinations.
On the basis of target organism, the segment of antibacterial has emerged as the largest market due to its significant share in the global economy. The contribution of the anti-bacterial segment is expected to grow further at a faster rate during the future as well. The increasing prevalence of diseases which spread through the mode of bacteria has boosted the market for the antibacterial segment to a great extent. Increasing prevalence of diseases such as hepatitis A, influenza, tuberculosis, HIV and hepatitis C Merged as a major opportunity for the growth of the anti-bacterial segment in the current market. Increasing disposable income available with the people has emerged as a major opportunity for the sales and demand of advanced antibacterial drugs in the market.
On the basis of infection type, the segment of bacterial infection has emerged as the fastest growing market over the period of time and is expected to show a tremendous boost during the future period as well. The increasing research and development programs conducted by the key market players with a view to introduce innovative medicines that are technologically advanced has helped the segment of bacterial infection to record a considerable growth over the period of time. The huge number of people who suffer with bacterial infection has also emerged as a major opportunity for the growth of the market. The weekend immunity system of the people provides a great opportunity for the bacteria to spread the infectious diseases and hence a considerable growth is recorded over the period of time.
On the basis of distribution channel, the segment of hospitals has emerged as the fastest growing market as it proves to be the primary center where a patient shows up first when they are infected buy an infection and hence this sector has recorded a considerable revenue over the period of time. The huge number of people visiting the hospital sector on a daily basis for treating infectious diseases has also proved to be a major growth factor for the market. Dream basement policies and other facilities provided by the hospital sector through the insurance companies emerges as an attractive opportunity for the growth of the market. A number of different facilities are available in the hospital sector which prevents the patient from running to different centers which emerges as another opportunity for the growth of the market.
On the basis of geography, the region of North America has emerged as the largest market for infectious disease therapeutics pertaining to the increasing prevalence of infectious diseases in this region. North America accounted highest revenue share 39% 2022. The huge number of people belonging to the geriatric population in this region has become a major growth factor for the infectious disease therapeutics market. Higher disposable income available with the people has also emerged as a major growth factor for the market. Advanced health care facilities provided by the government in the form of reimbursement policies has supported the growth of the market to a great extent.
The next region which has shown a tremendous growth is that of Asia Pacific which accounts for a considerable share in the global market for infectious disease therapeutics. The European region has also shown a considerable growth over the period of years.
Infectious Disease Therapeutics Market Share, By Region, 2022 (%)
| Regions | Revenue Share in 2022 (%) |
| North America | 39% |
| Asia Pacific | 26% |
| Europe | 22% |
| Latin America | 8.4% |
| MEA | 4.6% |
Segments covered in the report
By Mode of Treatment
By Target Organism
By Infection Type
By Distribution Channel
By Geography
PROCEED TO BUY :
ASK FOR SAMPLE
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
